MannKind names new chief executive

24 December 2015

US drugmaker MannKind Corp (Nasdaq: MNKD) today announced the appointment of Duane DeSisto as its president and chief executive, effective January 5, 2016, replacing Alfred Mann who has served as interim CEO since November 19, 2015.

Mr DeSisto was also appointed to fill an existing vacancy on the board of directors, effective January 5, 2016.

Previously, Mr DeSisto served as the CEO and president of Insulet Corp, a medical device company, from 2003 to 2014. From 2002 to 2003, he was president, chief financial officer and acting CEO of Insulet and, from 2001 to 2002, he served as the chief financial officer and treasurer of Insulet.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK